Patents by Inventor Juergen Daemmgen

Juergen Daemmgen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PDE III inhibitors for treatment of asymptomatic heart failure
    Patent number: 11413285
    Abstract: A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.
    Type: Grant
    Filed: September 11, 2018
    Date of Patent: August 16, 2022
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
    Patent number: 10537588
    Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 21, 2020
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
  • PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE
    Publication number: 20190008862
    Abstract: A method for treating a patient suffering from ISACHC Classification Class I heart failure includes administering to the patient a therapeutically effective amount of pimobendan or a pharmaceutically acceptable salt thereof, where the administration results in a reduction in the size of the patient's heart.
    Type: Application
    Filed: September 11, 2018
    Publication date: January 10, 2019
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • PDE III inhibitors for treatment of asymptomatic heart failure
    Patent number: 10117869
    Abstract: Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: November 6, 2018
    Assignee: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • USE OF PDE III INHIBITORS FOR THE REDUCTION OF HEART SIZE IN MAMMALS SUFFERING FROM HEART DISEASE
    Publication number: 20180185402
    Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Application
    Filed: January 9, 2018
    Publication date: July 5, 2018
    Inventors: Juergen DAEMMGEN, Olaf JOENS, Rainer KLEEMANN
  • Use of pimobendan for the reduction of heart size in mammals suffering from heart failure
    Patent number: 9889148
    Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 13, 2018
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
  • Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
    Patent number: 9463199
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Grant
    Filed: March 23, 2005
    Date of Patent: October 11, 2016
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann
  • H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
    Patent number: 9375469
    Abstract: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
    Type: Grant
    Filed: October 23, 2013
    Date of Patent: June 28, 2016
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Eric Martin Vaughn, Paulino Carlos Gonzalez-Hernandez, Juergen Daemmgen
  • Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
    Patent number: 8980894
    Abstract: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the reduction of heart size in patients having symptomatic or asymptomatic (occult) heart failure.
    Type: Grant
    Filed: June 11, 2009
    Date of Patent: March 17, 2015
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleemann, Christian Troetschel, Andrea Vollmar
  • Use of vaccines for the treatment/prevention of the transmission of pathogens
    Patent number: 8883123
    Abstract: The present invention relates to a method of reducing the transmission of a pathogen from an animal of a first species to an animal of a second species. Specifically, reduction of transmission is accomplished through the administration of antigen of the pathogen such that administration results in the reduction or absence of the reproduction of the pathogen in the animal to which the antigen was administered.
    Type: Grant
    Filed: October 27, 2006
    Date of Patent: November 11, 2014
    Assignee: Boehringer Ingleheim Vetmedica, Inc.
    Inventors: Juergen Daemmgen, Eric Martin Vaughn
  • USE OF PDE III INHIBITORS FOR THE REDUCTION OF HEART SIZE IN MAMMALS SUFFERING FROM HEART FAILURE
    Publication number: 20140155338
    Abstract: A phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof is provided for the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 5, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Juergen DAEMMGEN, Olaf JOENS, Rainer KLEEMANN
  • Phosphodiesterase type III (PDE III) inhibitors or CA-sensitizing agents for the treatment of hypertrophic cardiomyopathy
    Patent number: 8664252
    Abstract: The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and/or Ca2+-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: March 4, 2014
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens
  • NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE
    Publication number: 20140050755
    Abstract: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
    Type: Application
    Filed: October 23, 2013
    Publication date: February 20, 2014
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Eric Martin VAUGHN, Paulino Carlos GONZALEZ-HERNANDEZ, Juergen DAEMMGEN
  • Use of a Specific Cyclic Amine Derivative or the Pharmaceutically Acceptable Salts Thereof for the Treatment or Prevention of Heart Failure
    Publication number: 20130317008
    Abstract: The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment or prevention of heart failure of any aetiology.
    Type: Application
    Filed: August 1, 2013
    Publication date: November 28, 2013
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Brian GUTH, Randolph SEIDLER, Juergen DAEMMGEN
  • H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
    Patent number: 8592558
    Abstract: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: November 26, 2013
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Eric M. Vaughn, Paulino Carlos Gonzalez-Hernandez, Juergen Daemmgen
  • Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
    Patent number: 8524701
    Abstract: The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment of heart failure of any aetiology.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: September 3, 2013
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Brian Guth, Randolph Seidler, Juergen Daemmgen
  • PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE
    Publication number: 20130203690
    Abstract: Phosphodiesterase type III (PDE III) inhibitor or a “Ca2+-sensitizing agent” or a pharmaceutically acceptable derivative thereof is used in the preparation of a medication for the reduction of the heart size of a patient suffering from heart failure, and as a medication for the reverse remodeling of the heart of a patient with asymptomatic (occult) heart failure and their delayed onset of clinical symptoms.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 8, 2013
    Applicant: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Juergen Daemmgen, Olaf Joens, Rainer Kleeman, Christian Troetschel, Andrea Vollmar
  • NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE
    Publication number: 20120231027
    Abstract: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
    Type: Application
    Filed: May 21, 2012
    Publication date: September 13, 2012
    Applicant: BOEHRINGER INGELHEIM VETMEDICA, INC.
    Inventors: Eric VAUGHN, Paulino Carlos GONZALEZ-HERNANDEZ, Juergen DAEMMGEN
  • H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
    Patent number: 8202967
    Abstract: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.
    Type: Grant
    Filed: October 24, 2007
    Date of Patent: June 19, 2012
    Assignee: Boehringer Ingelheim Vetmedica, Inc.
    Inventors: Eric Vaughn, Paulino Carlos Gonzalez-Hernandez, Juergen Däemmgen
  • PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
    Publication number: 20110251208
    Abstract: The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca2+- sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and/or Ca2+-sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.
    Type: Application
    Filed: November 23, 2009
    Publication date: October 13, 2011
    Applicant: BOEHRINGER INGELHEIM VETMEDICA GMBH
    Inventors: Juergen Daemmgen, Olaf Joens